Comparación del efecto broncodilatador producido por ipratropio solo y la asociación de ipratropio con salbutamol en pacientes con epoc estable: hospitales José Carrasco Arteaga (IESS), Vicente Corral Moscoso (Cuenca), Fábrica de Cementos Guapan (Azogues) noviembre 2002-mayo 2003

Se compara el efecto broncodilatador entre un anticolinérgico (Ipratropio) y la asociación de éste más un B2 agonista de acción corta (Salbutano) en pacientes con E.P.O.C. estable secundariamente se valoró el cambio en la calidad de vida y se evaluaron efectos colaterales (postramiento) en cada grupo. Se realizaron 271 espirometrías de las cuales se seleccionaron 70 pacientes que cumplian los criterios de inclusión. Estos fueron asignados al azar a uno de los dos grupos de estudio: Atrovent o Conbivent y se realizó valoración clínica y espirométrica. El parámetro principal de desenlace fue el FEVI, se aplicó cuestionario de calidad de vida y cada paciente recibió el medicamento específico de acuerdo a su grupo. Transcurrido un mes se repitió las pruebas y se valoraron efectos colaterales. El resultado del estudio demostró efecto broncodilatador superior del Ipratropio solo versus la asociación. No se encontraron diferencias significativas en cuanto a calidad de vida entre los dos grupos a pesar de que ésta mejoró globalmene. Tampoco hubieron diferencias significativas en cuanto a efectos colaterales por grupo. Los hallazgos refutan la hipótesis de estudio. Los B2 agonistas de corta acción producen efecto broncodilatador únicamente dentro de las primeras cuatro horas post-inhalación. La valoración se enfocó en los efectos luego de un mes de utilización sin tomar en consideración el tiempo transcurrido desde la última inhalación, pues este trabajo pretende buscar la mejor opción terapéutica a largo plazo. El efecto bronodilatador que produce el Ipratropio es superior a aquel observado al utilizar la asociación. Esta diferencia es estadísticamente significativa. au

A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting

Background: Formoterol is a fast-acting, long-acting beta-agonist. Its on-demand use by outpatients has been beneficial in controlling asthma. Objective: To evaluate the efficacy of formoterol as rescue medication for pediatric asthma exacerbation. Methods: A randomized, double-blind study was conducted on parallel groups involving 79 pediatric patients (mean [SD] age, 9.92 [2.5] years) with mild to moderate asthma exacerbations. They were treated with up to 3 doses of formoterol aerolizer, 12 mu g, or terbutaline Turbuhaler, 0.5 mg (dry powder inhalers). Respiratory rate, clinical score, pulse oximetry, and spirometry were analyzed at baseline and 15 minutes after administration of each bronchodilator dose. All the patients received oral prednisolone, 1 mg/kg, at study entry, followed by a single daily dose for 4 days. Forty-one patients were treated with formoterol and 38 with terbutaline. The groups were comparable in age and in severity of asthma exacerbation. Results: Both treatments resulted in similar clinical and functional improvement; 37 patients (47%) required 1 bronchodilator dose. Increases of 19.5% and 1.5.3% occurred in forced expiratory volume in 1 second in the formoterol and terbutaline groups, respectively. Therapeutic failures occurred in 2 patients. No adverse effects were observed. At 1-week follow-up, patients were stable, with pulmonary function close to normal. Conclusion: Formoterol therapy was at least as effective as terbutaline therapy in children and adolescents with mild and moderate asthma exacerbations. Ann Allergy Asthma Immunol. 2009; 103:248-253.

Effects of Ipratropium on Exercise-Induced Bronchospasm

Exercise-induced bronchospasm (EIB) is the transient narrowing of the airways that follows vigorous exercise. Ipratropium bromide may be used to prevent EIB, but its effect varies among individuals. We hypothesized that time of administration of ipratropium interferes with its action. This was a prospective, double-blind, cross-over study carried out to evaluate the bronchoprotective and bronchodilatory effect of ipratropium at different times of day. The study consisted of 4 exercise challenge tests (2 at 7 am and 2 at 6 pm). In the morning, one of the tests was performed after placebo administration and the other one after ipratropium (80 mu g) and the two tests (placebo and ipratropium) were repeated in the evening. Twenty-one patients with severe or moderate asthma and previous confirmation of EIB were enrolled in this prospective trial. The bronchodilatory effect of ipratropium was 0.25 +/- 0.21 L or 13.11 +/- 10.99 % (p = 0.001 compared to baseline values) in the morning, and 0.14 +/- 0.25 L or 7.25 +/- 11.37 % (p > 0.05) in the evening. In the morning, EIB was 0.58 +/- 0.29 L on the placebo day and 0.38 +/- 0.22 L on the treatment day (p = 0.01). In the evening, EIB was 0.62 +/- 0.28 L on the placebo day and 0.51 +/- 0.35 L on the treatment day (p > 0.05). We suggest that the use of ipratropium for the treatment of asthma and EIB should take into consideration the time of administration.

Contribution of hospital effluents to the load of pharmaceuticals in urban wastewaters: Identification of ecologically relevant pharmaceuticals

The impact of effluent wastewaters from four different hospitals: a university (1456 beds), a general (350 beds), a pediatric (110 beds) and a maternity hospital (96 beds), which are conveyed to the same wastewater treatment plant (WWTP), was evaluated in the receiving urban wastewaters. The occurrence of 78 pharmaceuticals belonging to several therapeutic classes was assessed in hospital effluents and WWTP wastewaters (influent and effluent) as well as the contribution of each hospital in WWTP influent in terms of pharmaceutical load. Results indicate that pharmaceuticals are widespread pollutants in both hospital and urban wastewaters. The contribution of hospitals to the input of pharmaceuticals in urban wastewaters widely varies, according to their dimension. The estimated total mass loadings were 306 g d− 1 for the university hospital, 155 g d− 1 for the general one, 14 g d− 1 for the pediatric hospital and 1.5 g d− 1 for the maternity hospital, showing that the biggest hospitals have a greater contribution to the total mass load of pharmaceuticals. Furthermore, analysis of individual contributions of each therapeutic group showed that NSAIDs, analgesics and antibiotics are among the groups with the highest inputs. Removal efficiency can go from over 90% for pharmaceuticals like acetaminophen and ibuprofen to not removal for β-blockers and salbutamol. Total mass load of pharmaceuticals into receiving surface waters was estimated between 5 and 14 g/d/1000 inhabitants. Finally, the environmental risk posed by pharmaceuticals detected in hospital and WWTP effluents was assessed by means of hazard quotients toward different trophic levels (algae, daphnids and fish). Several pharmaceuticals present in the different matrices were identified as potentially hazardous to aquatic organisms, showing that especial attention should be paid to antibiotics such as ciprofloxacin, ofloxacin, sulfamethoxazole, azithromycin and clarithromycin, since their hazard quotients in WWTP effluent revealed that they could pose an ecotoxicological risk to algae.

Enantiomeric fraction evaluation of pharmaceuticals in environmentalmatrices by liquid chromatography-tandem mass spectrometry

The interest for environmental fate assessment of chiral pharmaceuticals is increasing and enantioselective analytical methods are mandatory. This study presents an enantioselective analytical method for the quantification of seven pairs of enantiomers of pharmaceuticals and a pair of a metabolite. The selected chiral pharmaceuticals belong to three different therapeutic classes, namely selective serotonin reuptake inhibitors (venlafaxine, fluoxetine and its metabolite norfluoxetine), beta-blockers (alprenolol, bisoprolol, metoprolol, propranolol) and a beta2-adrenergic agonist (salbutamol). The analytical method was based on solid phase extraction followed by liquid chromatography tandem mass spectrometry with a triple quadrupole analyser. Briefly, Oasis® MCX cartridges were used to preconcentrate 250 mL of water samples and the reconstituted extracts were analysed with a Chirobiotic™ V under reversed mode. The effluent of a laboratory-scale aerobic granular sludge sequencing batch reactor (AGS-SBR) was used to validate the method. Linearity (r2 > 0.99), selectivity and sensitivity were achieved in the range of 20–400 ng L−1 for all enantiomers, except for norfluoxetine enantiomers which range covered 30–400 ng L−1. The method detection limits were between 0.65 and 11.5 ng L−1 and the method quantification limits were between 1.98 and 19.7 ng L−1. The identity of all enantiomers was confirmed using two MS/MS transitions and its ion ratios, according to European Commission Decision 2002/657/EC. This method was successfully applied to evaluate effluents of wastewater treatment plants (WWTP) in Portugal. Venlafaxine and fluoxetine were quantified as non-racemic mixtures (enantiomeric fraction ≠ 0.5). The enantioselective validated method was able to monitor chiral pharmaceuticals in WWTP effluents and has potential to assess the enantioselective biodegradation in bioreactors. Further application in environmental matrices as surface and estuarine waters can be exploited.

Repercussões crónicas nas vias aéreas da hiperóxia neonatal : modelo experimental

RESUMO: O objectivo deste trabalho foi avaliar se a exposição crónica neonatal à hiperóxia mo-derada induz alterações funcionais e estruturais persistentes nas vias aéreas. Desenvolveu-se um modelo animal, no rato, a partir do qual se retiraram implicações para a compreensão das repercussões crónicas da hiperóxia neonatal sobre as vias aéreas de displasia broncopulmonar (DBP), em duas fases distintas: imediatamente após a exposi-ção neonatal a 50%O2 (grupo 50%O2) e após três semanas de recuperação em ar ambiente (grupo 50%O2+Ar).Compararam-se os resultados da resposta do músculo liso de traqueia (MLT) à esti-mulação in vitro com metacolina e salbutamol e avaliaram-se as alterações quantitativas da área de MLT, bem como as alterações qualitativas da estrutura da traqueia. Demonstrou-se que a exposição a 50% de oxigénio não tinha repercussões imediatas sobre a resposta in vitro do MLT à estimulação colinérgica, mas que induzia um aumento do relaxamento em resposta ao salbutamol. A contractilidade do MLT em resposta à estimula-ção com metacolina no grupo 50%O2+Ar foi significativamente superior à do grupo de con-trolo da mesma idade e também superior à observada no grupo 50%O2, enquanto que a resposta ao salbutamol se voltou a aproximar dos valores de controlo após a recuperação em normóxia. Não se observaram diferenças estatisticamente significativas na área de MLT entre os grupos experimental e de controlo, o que se deve provavelmente ao número reduzido de amostras avaliadas e à variabilidade deste parâmetro no grupo de controlo; contudo, verifi-cou-se um aumento médio de 15% imediatamente após a exposição à hiperóxia que persis-tiu após o período de recuperação.As alterações qualitativas sobre a arquitectura da traqueia, avaliadas por microscopia óptica, revelaram no grupo 50%O2 aumentos da espessura da matriz extracelular e da den-sidade de mastócitos desgranulados na submucosa e adventícia vizinhas do MLT, sem outras alterações relativamente ao grupo de controlo com 15 dias. As alterações da matriz extrace-lular foram reversíveis após a recuperação em ar ambiente. A densidade de mastócitos per-maneceu superior à do grupo de controlo de 36 dias de idade, apresentando-se em maior contiguidade com o MLT relativamente ao grupo 50%O2. Em síntese, demonstrou-se que a hiperóxia neonatal crónica em níveis moderados in-duz alterações da resposta contráctil do MLT e da estrutura da traqueia que podem ter ex-pressão funcional após a exposição ter cessado. Assim, o contributo original do presente trabalho foi o desenvolvimento de um modelo animal que permite avaliar os mecanismos pelos quais a hiperóxia é capaz de induzir, isoladamente, alterações crónicas da contracti-lidade, do relaxamento do ML e da estrutura das vias aéreas que podem ser responsáveis pela HRB persistente em doentes sujeitos a oxigenioterapia neonatal.-------------ABSTRACT: The aim of this work was to evaluate whether chronic neonatal exposure to hyperoxia in-duces persistent structural and functional airway changes. An animal model was developed, using neonatal rats, in order to understand the chronic effects of neonatal hyperoxia on the airways, in bronchopulmonary dysplasia, in two distinct phases: immediately after neonatal exposure to 50%O2 (50%O2 group) and after three weeks of recovery at ambient air (50%O2+Ar group).The results from the tracheal smooth muscle (TSM) response to in vitro stimulation with metacholine and salbutamol were compared and quantitative changes in TSM area, as well as qualitative changes in tracheal structure were evaluated. It was demonstrated that while exposure to 50% oxygen had no immediate effects on in vitro TSM response to cholinergic stimulation, it induced an increase in relaxation as a result of salbutamol administration. TSM contractility as a result of methacholine administration in the 50%O2 + Ar group was significantly higher than that of the same-age control group, and also higher than the one observed in the 50%O2 group, whereas the response to salbutamol admini-stration was once again closer to the control values after recovery in normoxia. There were no statistically significant differences in the TSM area between the experi-mental and control groups, which is most likely due to the reduced number of samples evalu-ated and to the variability of this parameter in the control group. However, there was an aver-age increase of 15% immediately after exposure to hyperoxia, which persisted after the recov-ery period. Qualitative changes in tracheal architecture, evaluated by optic microscopy, revealed that the 50%O2 group suffered an increase in the thickness of the extracellular matrix and degranu-lated mast cell density in the submucosa and adventitia adjacent to the TSM, without further changes when compared with the control group at 15 days of age. The changes in extracellular matrix were reversible after recovery in ambient air. Mast cell density remained higher than that of the control group at 36 days of age, and more contiguous to TSM than the 50%O2 group. In conclusion, it has been demonstrated that moderate levels of chronic neonatal hyperoxia in-duce changes in TSM contractile response and tracheal structure, which may be functionally ex-pressed after discontinuation of exposure. Therefore, the original contribution of the present work was the development of an animal model which allows the evaluation of the mechanisms through which hyperoxia alone can induce chronic changes in contractility and relaxation of SM and also in airway structure that can be responsible for the persistent airway hyperrespon-siveness found in patients who were submited to neonatal oxygen therapy.

Espirometria Pré-Escolar: Estudo de uma População - Que Implicações?

A espirometria é uma ferramenta major para o estudo de doentes com várias patologias, nomeadamente respiratórias, comumente usada em adultos e em crianças mais velhas. A idade pré-escolar tem sido a "idade das trevas" para a função pulmonar até aos últimos anos, pela necessiadade de cooperação e impraticabilidade de sedação. Objectivo: Determinar o número de crianças em que se torna possível efectuar espirometrias em idade pré-escolar, em função da sua idade, cumprindo critérios de aceitabilidade e exequibilidade das curvas débito-volume. Metodologia: Entre os meses de Março e Junho de 2004 foram efectuadas espirometrias animadas com equipamento Jaeger, a um grupo de 53 crianças, admitidas na Consulta de Imunoalergologia do nosso hospital por quadro clínico de asma, tosse crónica ou queixas de esforço. Foram efectuadas a cada criança 15 manobras expiratórias, antes e após a administração de 400ug de salbutamol, em câmara expansora, sendo utilizados critérios de aceitabilidade e reprodutibilidade de espirometria, paar esta faixa etária, publicados recentemente por urora et al. Resultados: De universo alvo (n=53) foi possível obter curvas em critérios de aceitabilidade e reprodutibilidade em 44 crianças (85%), com uma média etária de 4,8 anos (2-6anos) e ratio M/F de 2,2/l. Obteve-se FEV, em 22 crianças (42%), FEV 0,75 em 32 (60%) e FEV 0,5 em 45 (85%). Analisando a globalidade da população em estudo, reporta-se um ganho de 45% usando FEV 0,75 em vez de FEV 1, bem como um ganho de 104% reportando FEV 0,5 em vez de FEV 1. Tempo médio de exame, incluindo prova de broncodilatação:1,30h (35min-2h), 22% (n=10) tinham padrão obstrutivo basal, dos quais 6 tiveram prova de broncodilatção positiva. Conclusões: As crianças com 2 e 3 anos conseguiram efectuar manobras de duração máxima de 0,5 e 0,75 segundos, respectivamente. O grau de sucesso para manobras de maior duração é proporcional à idade. No período inter-crise, 22% tinham padrão obstrutivo basal, alguns dos quais com reversibilidade. A espirometria em idade pré-escolar é uma excelente ferramenta que pode ser utilizada diariamente, possibilitando analisar um grande número de crianças, que seria impossível utilizando os critérios empregues no adulto.

Búsqueda e identificación de polimorfismos en genes asociados con una efectividad farmacológica disminuida. Caracterización molecular, hallazgos bioquímicos y clínicos y su respectiva correlación con la respuesta farmacológica en el tratamiento de enfermedades crónicas e infecciosas

En medicina, es frecuente encontrar diferencias en la respuesta de una misma droga en distintos individuos. Algunos factores que contribuyen con esta respuesta diferencial incluyen variables como edad, biodisponilidad y absorción gastro-intestinal de los medicamentos, interacción entre fármacos, hábitos alimentarios y factores genéticos. Dentro de los factores genéticos, encontramos polimorfismos genéticos que afectan la absorción, el metabolismo y el transporte de fármacos, como así también receptores de los mismos y/o, la interacción con otros genes. Algunos polimorfismos genéticos que contribuyen a una respuesta farmacológica disminuida han sido descriptos en patologías como, la hipercolesterolemia, artritis reumatoidea, cáncer, diabetes, hipertensión arterial, esquizofrenia, asma, hepatitis C y SIDA, entre otras. Nuestro estudio pretende: I) Identificar polimorfismos en genes que codifican para enzimas metabolizadoras de fármacos, para canales iónicos y, para receptores de fármacos (como por ejemplo polimorfismos en el receptor beta 2 adrenérgico en pacientes tratados con salbutamol que presentan bronquiolitis). II) Identificar la presencia de un polimorfismo en el gen CES 1 que codifica para la enzima carboxilesterasa 1 (en una población hospitalaria), que participa en la activación de la prodroga oseltamivir utilizada en el tratamiento de la Gripe A (H1N1). Los resultados obtenidos podrán ser de gran utilidad en el tratamiento médico, ya que permitirá optimizar el uso de fármacos, disminuir los efectos secundarios causados por los mismos, y proponer el empleo de otros fármacos

Búsqueda e identificación de polimorfismos en genes asociados con una efectividad farmacológica disminuida. Caracterización molecular, hallazgos bioquímicos y clínicos y su respectiva correlación con la respuesta farmacológica en el tratamiento de enfermedades crónicas e infecciosas.

En medicina, es frecuente encontrar diferencias en la respuesta de una misma droga en distintos individuos. Algunos factores que contribuyen con esta respuesta diferencial incluyen variables como edad, biodisponilidad y absorción gastro-intestinal de los medicamentos, interacción entre fármacos, hábitos alimentarios y factores genéticos. Dentro de los factores genéticos, encontramos polimorfismos genéticos que afectan la absorción, el metabolismo y el transporte de fármacos, como así también receptores de los mismos y/o, la interacción con otros genes. Algunos polimorfismos genéticos que contribuyen a una respuesta farmacológica disminuida han sido descriptos en patologías como, la hipercolesterolemia, artritis reumatoidea, cáncer, diabetes, hipertensión arterial, esquizofrenia, asma, hepatitis C y SIDA, entre otras. Nuestro estudio pretende: I) Identificar polimorfismos en genes que codifican para enzimas metabolizadoras de fármacos, para canales iónicos y, para receptores de fármacos (como por ejemplo polimorfismos en el receptor beta 2 adrenérgico en pacientes tratados con salbutamol que presentan bronquiolitis). II) Identificar la presencia de un polimorfismo en el gen CES 1 que codifica para la enzima carboxilesterasa 1 (en una población hospitalaria), que participa en la activación de la prodroga oseltamivir utilizada en el tratamiento de la Gripe A (H1N1). Los resultados obtenidos podrán ser de gran utilidad en el tratamiento médico, ya que permitirá optimizar el uso de fármacos, disminuir los efectos secundarios causados por los mismos, y proponer el empleo de otros fármacos.

Estimulació beta-adrenèrgica en la síndrome del destret respiratori agut (SDRA)

Estudi elaborat a partir d’una estada al Royal Brompton Hospital, Londres, Regne Unit, durant octubre i novembre del 2006.Els beneficis de la estimulació beta-adrenèrgica en pacients amb lesió pulmonar aguda (LPA) són coneguts, però no es disposa de dades sobre el possible efecte antiinflamatori. El condensat d'aire exhalat (CAE) és una tècnica no-invasiva de recollida de mostres del tracte respiratori inferior, podent ser útil en la monitorització de patologies respiratòries. S’ha usat marcadors biològics en el CAE de pacients ventilats mecànicament amb LPA per estudiar el possible efecte antiinflamatori que el salbutamol hi podria exercir. El CAE va ser recollit abans i després de l'administració de salbutamol inahalat. Inmediatament després es va mesurar la conductivitat i el pH abans i després de la desgasificació amb heli. Es va mesurar la concentració de nitrits i nitrats. Les mostres varen ser liofilitzades i guardades a -80ºC. La concentració de leucotriè B4 es va mesurar després de la reconstitució de la mostra. Els resultats s'expressen com a mitjana (error estàndard de la mostra). No s'han detectat diferències entre els valors de CAE basals dels pacients amb LPA i els de referència de la població sana de Barcelona. Es conclou doncs que el CAE és una tècnica no invasiva que pot ser usada en la monitorització de paceints ventilats mecànicament. El salbutamol inhalat incrementa de manera significativa el pH del CAE dels paceints amb LPA, tot i que un efecte directe de la inhalació de slabutamol no pot ser desestimat.

Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease.

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are frequently malnourished and have increased resting energy expenditure (REE). An increase in the work of breathing is generally considered to be the main cause of this hypermetabolism, but other factors may also be implicated. Bronchodilators may decrease the work of breathing by reducing airway obstruction, but beta 2 adrenergic agents have a thermogenic effect. The aim of this study was to determine the effect of salbutamol and ipratropium bromide administration on REE in patients with COPD. METHODS: Thirteen patients (10 men) of mean (SD) age 68.3 (7.3) years and forced expiratory volume in one second (FEV1) 39.0 (17.0)% predicted were studied on three consecutive days. The REE was measured by indirect calorimetry at 30, 60, 120, and 180 minutes after double blind nebulisation of either salbutamol, ipratropium bromide, or placebo in random order. RESULTS: FEV1 increased both after salbutamol and after ipratropium. The difference in the mean response between salbutamol and placebo over 180 minutes was +199 ml (95% CI +104 to +295). The difference in mean response between ipratropium and placebo was +78 ml (95% CI +2 to +160). REE increased after salbutamol but was not changed after ipratropium. The difference in mean response between salbutamol and placebo was +4.8% of baseline REE (95% CI +2.2 to +7.4). Heart rate increased after salbutamol but not after ipratropium. The difference in the mean response between salbutamol and placebo was +5.5 beats/ min (95% CI +2.6 to +8.4). CONCLUSION: Salbutamol, but not ipratropium bromide, induces a sustained increase in the REE of patients with COPD despite a reduction in airway obstruction.

Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study.

BACKGROUND: Pregnant women with asthma need to take medication during pregnancy. OBJECTIVE: We sought to identify whether there is an increased risk of specific congenital anomalies after exposure to antiasthma medication in the first trimester of pregnancy. METHODS: We performed a population-based case-malformed control study testing signals identified in a literature review. Odds ratios (ORs) of exposure to the main groups of asthma medication were calculated for each of the 10 signal anomalies compared with registrations with nonchromosomal, nonsignal anomalies as control registrations. In addition, exploratory analyses were done for each nonsignal anomaly. The data set included 76,249 registrations of congenital anomalies from 13 EUROmediCAT registries. RESULTS: Cleft palate (OR, 1.63; 95% CI, 1.05-2.52) and gastroschisis (OR, 1.89; 95% CI, 1.12-3.20) had significantly increased odds of exposure to first-trimester use of inhaled β2-agonists compared with nonchromosomal control registrations. Odds of exposure to salbutamol were similar. Nonsignificant ORs of exposure to inhaled β2-agonists were found for spina bifida, cleft lip, anal atresia, severe congenital heart defects in general, or tetralogy of Fallot. None of the 4 literature signals of exposure to inhaled steroids were confirmed (cleft palate, cleft lip, anal atresia, and hypospadias). Exploratory analyses found an association between renal dysplasia and exposure to the combination of long-acting β2-agonists and inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85). CONCLUSIONS: The study confirmed increased odds of first-trimester exposure to inhaled β2-agonists for cleft palate and gastroschisis and found a potential new signal for renal dysplasia associated with combined long-acting β2-agonists and inhaled corticosteroids. Use of inhaled corticosteroids during the first trimester of pregnancy seems to be safe in relation to the risk for a range of specific major congenital anomalies.

The mechanism of gentisic acid-induced relaxation of the guinea pig isolated trachea: the role of potassium channels and vasoactive intestinal peptide receptors

We examined some of the mechanisms by which the aspirin metabolite and the naturally occurring metabolite gentisic acid induced relaxation of the guinea pig trachea in vitro. In preparations with or without epithelium and contracted by histamine, gentisic acid caused concentration-dependent and reproducible relaxation, with mean EC50 values of 18 µM and Emax of 100% (N = 10) or 20 µM and Emax of 92% (N = 10), respectively. The relaxation caused by gentisic acid was of slow onset in comparison to that caused by norepinephrine, theophylline or vasoactive intestinal peptide (VIP). The relative rank order of potency was: salbutamol 7.9 > VIP 7.0 > gentisic acid 4.7 > theophylline 3.7. Gentisic acid-induced relaxation was markedly reduced (24 ± 7.0, 43 ± 3.9 and 78 ± 5.6%) in preparations with elevated potassium concentration in the medium (20, 40 or 80 mM, respectively). Tetraethylammonium (100 µM), a nonselective blocker of the potassium channels, partially inhibited the relaxation response to gentisic acid, while 4-AP (10 µM), a blocker of the voltage potassium channel, inhibited gentisic acid-induced relaxation by 41 ± 12%. Glibenclamide (1 or 3 µM), at a concentration which markedly inhibited the relaxation induced by the opener of ATP-sensitive K+ channels, levcromakalim, had no effect on the relaxation induced by gentisic acid. Charybdotoxin (0.1 or 0.3 µM), a selective blocker of the large-conductance Ca2+-activated K+ channels, caused rightward shifts (6- and 7-fold) of the gentisic acid concentration-relaxation curve. L-N G-nitroarginine (100 µM), a NO synthase inhibitor, had no effect on the relaxant effect of gentisic acid, and caused a slight displacement to the right in the relaxant effect of the gentisic acid curve at 300 µM, while methylene blue (10 or 30 µM) or ODQ (1 µM), the inhibitors of soluble guanylate cyclase, all failed to affect gentisic acid-induced relaxation. D-P-Cl-Phe6,Leu17[VIP] (0.1 µM), a VIP receptor antagonist, significantly inhibited (37 ± 7%) relaxation induced by gentisic acid, whereas CGRP (8-37) (0.1 µM), a CGRP antagonist, only slightly enhanced the action of gentisic acid. Taken together, these results provide functional evidence for the direct activation of voltage and large-conductance Ca+2-activated K+ channels, or indirect modulation of potassium channels induced by VIP receptors and accounts for the predominant relaxation response caused by gentisic acid in the guinea pig trachea.

Correlations between pulse oximetry and peak expiratory flow in acute asthma

Few studies are available concerning correlations between pulse oximetry and peak expiratory flow in children and adolescents with acute asthma. Although the Global Initiative for Asthma states that measurements of lung function and oximetry are critical for the assessment of patients, it is not clear if both methods should necessarily be included in their evaluation. Since there is a significant difference in cost between pulse oximetry equipment and peak expiratory flow devices, we determined whether clinical findings and peak expiratory flow measurements are sufficient to determine the severity of acute asthma. The present prospective observational study was carried out to determine if there is correlation between pulse oximetry and peak expiratory flow determination in 196 patients with acute asthma aged 4 to 15 years diagnosed according to the Global Initiative for Asthma criteria. Patients experiencing their first or second wheezing episode, with fever, related acute or chronic diseases, and unable to perform the peak expiratory flow maneuver were excluded. Measurements of peak expiratory flow and pulse oximetry were performed at admission and after 15 min of each inhaled salbutamol cycle. Correlations obtained by linear regression using the Pearson correlation coefficients (r) were 0.41 (P < 0.0001), 0.53 (P < 0.0001), 0.51 (P < 0.0001), and 0.61 (P < 0.0001) at admission and after the first, second and third cycles of salbutamol, respectively. These correlations showed that one measure cannot substitute the other (Pearson's coefficient <0.7), probably because they evaluate different aspects in the airways, suggesting that peak expiratory flow should not be used alone in the assessment of acute asthma in children and adolescents.

Caracterización de la población con bronquiolitis en la Clínica infantil Colsubsidio en el año 2013

Introducción: La bronquiolitis es la infección viral más común del tracto respiratorio en menores de 2 años. En Colombia existen pocos estudios respecto a este tema, lo cual nos motivó a realizar un estudio para evaluar el panorama actual de la población Colombiana. Objetivo: Caracterizar la población hospitalizada con diagnóstico de bronquiolitis en la Clínica Infantil Colsubsidio Materiales y Método: Es un estudio descriptivo – retrospectivo donde se revisaron variables demográficas, clínicas, paraclínicas y de tratamiento, en las historias clínicas de pacientes hospitalizados con bronquiolitis en la Clínica Infantil Colsubsidio. Resultados: Se evaluaron 1230 historias, 906 cumplieron criterios de inclusión. Un 55,7% fueron niños. La edad promedio fue de 5,5 meses. El principal factor de riesgo fue ser pretérmino (57%). El principal germen aislado fue el Virus Sincitial Respiratorio, seguido por el adenovirus. En cuanto al manejo, el medicamento más utilizado fue el salbutamol en el 98%, con un uso de antibióticos en el 25%, siendo la razón de su uso la sospecha de coinfección bacteriana. El 65,78% tuvo una estancia hospitalaria menor a 5 días y el 3,64% requirió ingreso a la Unidad de Cuidados intensivos. La mortalidad fue 0%. Conclusión: Las características demográficas de nuestra población, el comportamiento de la enfermedad, requerimiento de UCI y la estancia hospitalaria son similares a los descritos en la literatura mundial. Evidenciamos un gran número de ayudas diagnósticas y uso de medicamentos, que obliga a replantearnos el manejo que damos y adherirnos a la evidencia actual